Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENXBIO Inc.RGNX · Entity 2211 | Director · Chief Executive Officer | December 31, 2025 | July 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENXBIO Inc.
Report date December 31, 2025 · Filed July 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 343,418 |
Reported balance
After 2025-12-31 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-12-31 · Grant · Acquired 951 · Balance 343,418 F1: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the REGENXBIO Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of July 1, 2025 through December 31, 2025. This transaction is exempt under Rule 16b-3(c). F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on July 1, 2025. |
| Common StockSEC Table I · non-derivative | Direct | 344,871 |
Reported balance
After 2026-06-30 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-06-30 · Grant · Acquired 1,453 · Balance 344,871 F3: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the ESPP for the ESPP purchase period of January 1, 2026 through June 30, 2026. This transaction is exempt under Rule 16b-3(c). F4: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on June 30, 2026. |
| Common StockSEC Table I · non-derivative | Direct | 338,053 |
Reported balance
After 2026-07-01 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-07-01 · Tax withholding · Disposed 6,818 · Balance 338,053 F5: Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on July 1, 2024. The number of shares withheld was determined based on the closing price of the issuer's common stock on July 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the REGENXBIO Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of July 1, 2025 through December 31, 2025. This transaction is exempt under Rule 16b-3(c).
F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on July 1, 2025.
F3: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the ESPP for the ESPP purchase period of January 1, 2026 through June 30, 2026. This transaction is exempt under Rule 16b-3(c).
F4: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on June 30, 2026.
F5: Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on July 1, 2024. The number of shares withheld was determined based on the closing price of the issuer's common stock on July 1, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 10, 2020 Filed Feb 12, 2020 21:27 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 4,253 | $19.50 | $82,933.50 |
DisclosureSEC source: 0001562180-20-001112 · primarydocument.xml · nonDerivative · entry 1 Simpson Curran · CIK 0001346164 · SVP, Product Development & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,901 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:23 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,708 | $0.00 Strike: $13.09 | $0.00 |
DisclosureSEC source: 0001562180-20-001015 · primarydocument.xml · derivative · entry 9 Simpson Curran · CIK 0001346164 · SVP, Product Development & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,708 shares Expires 2026-01-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F6 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 10,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 28, 2017, and the balance vested in equal monthly installments over the 36 months thereafter. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:23 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $19.50 | $0.00 |
DisclosureSEC source: 0001562180-20-001015 · primarydocument.xml · derivative · entry 8 Simpson Curran · CIK 0001346164 · SVP, Product Development & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,378 Underlying: Common Stock · 1,000 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F5 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 30,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 4, 2018, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:23 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Option (Right to Buy) · Derivative | 958 | $0.00 Strike: $22.00 | $0.00 |
DisclosureSEC source: 0001562180-20-001015 · primarydocument.xml · derivative · entry 7 Simpson Curran · CIK 0001346164 · SVP, Product Development & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,561 Underlying: Common Stock · 958 shares Expires 2025-08-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 230,500 shares, became exercisable as follows: 25% of the shares subject to this option vested on August 31, 2016, and the balance vested in equal monthly installments over the 36 months thereafter. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:23 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Option (Right to Buy) · Derivative | 471 | $0.00 Strike: $35.80 | $0.00 |
DisclosureSEC source: 0001562180-20-001015 · primarydocument.xml · derivative · entry 6 Simpson Curran · CIK 0001346164 · SVP, Product Development & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,979 Underlying: Common Stock · 471 shares Expires 2028-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 55,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 3, 2019, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:23 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 5,637 | $50.00 | $281,850.00 |
DisclosureSEC source: 0001562180-20-001015 · primarydocument.xml · nonDerivative · entry 5 Simpson Curran · CIK 0001346164 · SVP, Product Development & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,648 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $50.00 to $50.05. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:23 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 471 | $35.80 | $16,861.80 |
DisclosureSEC source: 0001562180-20-001015 · primarydocument.xml · nonDerivative · entry 4 Simpson Curran · CIK 0001346164 · SVP, Product Development & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,285 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:23 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 958 | $22.00 | $21,076.00 |
DisclosureSEC source: 0001562180-20-001015 · primarydocument.xml · nonDerivative · entry 3 Simpson Curran · CIK 0001346164 · SVP, Product Development & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,814 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:23 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 1,000 | $19.50 | $19,500.00 |
DisclosureSEC source: 0001562180-20-001015 · primarydocument.xml · nonDerivative · entry 2 Simpson Curran · CIK 0001346164 · SVP, Product Development & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,856 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:23 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 2,708 | $13.09 | $35,447.72 |
DisclosureSEC source: 0001562180-20-001015 · primarydocument.xml · nonDerivative · entry 1 Simpson Curran · CIK 0001346164 · SVP, Product Development & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,856 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 17, 2020 Filed Jan 21, 2020 21:18 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,622 | $0.00 Strike: $19.50 | $0.00 |
DisclosureSEC source: 0001562180-20-000454 · primarydocument.xml · derivative · entry 7 Simpson Curran · CIK 0001346164 · SVP, Product Development & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,378 Underlying: Common Stock · 1,622 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F5 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 30,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 4, 2018, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer. Read SEC document |
| January 17, 2020 Filed Jan 21, 2020 21:18 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,700 | $0.00 Strike: $22.00 | $0.00 |
DisclosureSEC source: 0001562180-20-000454 · primarydocument.xml · derivative · entry 6 Simpson Curran · CIK 0001346164 · SVP, Product Development & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,519 Underlying: Common Stock · 2,700 shares Expires 2025-08-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 230,500 shares, became exercisable as follows: 25% of the shares subject to this option vested on August 31, 2016, and the balance vested in equal monthly installments over the 36 months thereafter. Read SEC document |
| January 17, 2020 Filed Jan 21, 2020 21:18 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Option (Right to Buy) · Derivative | 800 | $0.00 Strike: $35.80 | $0.00 |
DisclosureSEC source: 0001562180-20-000454 · primarydocument.xml · derivative · entry 5 Simpson Curran · CIK 0001346164 · SVP, Product Development & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,450 Underlying: Common Stock · 800 shares Expires 2028-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 55,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 3, 2019, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer. Read SEC document |
| January 17, 2020 Filed Jan 21, 2020 21:18 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 5,922 | $50.00 | $296,100.00 |
DisclosureSEC source: 0001562180-20-000454 · primarydocument.xml · nonDerivative · entry 4 Simpson Curran · CIK 0001346164 · SVP, Product Development & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,148 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $50.00 to $50.04. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 17, 2020 Filed Jan 21, 2020 21:18 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 800 | $35.80 | $28,640.00 |
DisclosureSEC source: 0001562180-20-000454 · primarydocument.xml · nonDerivative · entry 3 Simpson Curran · CIK 0001346164 · SVP, Product Development & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,070 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 17, 2020 Filed Jan 21, 2020 21:18 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 2,700 | $22.00 | $59,400.00 |
DisclosureSEC source: 0001562180-20-000454 · primarydocument.xml · nonDerivative · entry 2 Simpson Curran · CIK 0001346164 · SVP, Product Development & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,270 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 17, 2020 Filed Jan 21, 2020 21:18 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 1,622 | $19.50 | $31,629.00 |
DisclosureSEC source: 0001562180-20-000454 · primarydocument.xml · nonDerivative · entry 1 Simpson Curran · CIK 0001346164 · SVP, Product Development & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,570 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:24 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Option (Right to Buy) · Derivative | 46,000 | $0.00 Strike: $38.99 | $0.00 |
DisclosureSEC source: 0001562180-20-000219 · primarydocument.xml · derivative · entry 1 Simpson Curran · CIK 0001346164 · SVP, Product Development & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,000 Underlying: Common Stock · 46,000 shares Expires 2030-01-02 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 2, 2021 while the optionee provides continuous service to the Issuer. Read SEC document |
| December 09, 2019 Filed Dec 11, 2019 21:24 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 6,153 | $44.26 | $272,331.78 |
DisclosureSEC source: 0001562180-19-006017 · primarydocument.xml · nonDerivative · entry 2 Simpson Curran · CIK 0001346164 · SVP, Product Development & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,948 F1 · kind: This sale was made pursuant to the Reporting Person's election under the Issuer's equity incentive plan and applicable award agreement to satisfy tax withholding obligations through a "sell to cover" transaction in connection with the vesting of 39,500 restricted stock unit shares awarded on December 8, 2016. This sale does not represent a discretionary trade by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $44.04 to $44.96. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 09, 2019 Filed Dec 11, 2019 21:24 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 9,399 | $43.40 | $407,916.60 |
DisclosureSEC source: 0001562180-19-006017 · primarydocument.xml · nonDerivative · entry 1 Simpson Curran · CIK 0001346164 · SVP, Product Development & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,101 F1 · kind: This sale was made pursuant to the Reporting Person's election under the Issuer's equity incentive plan and applicable award agreement to satisfy tax withholding obligations through a "sell to cover" transaction in connection with the vesting of 39,500 restricted stock unit shares awarded on December 8, 2016. This sale does not represent a discretionary trade by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $43.038 to $44.03. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 28, 2019 Filed May 30, 2019 20:56 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $22.00 | $0.00 |
DisclosureSEC source: 0001562180-19-003180 · primarydocument.xml · derivative · entry 3 Simpson Curran · CIK 0001346164 · SVP, Product Development & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,219 Underlying: Common Stock · 18,000 shares Expires 2025-08-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 230,500 shares, became exercisable as follows: 25% of the shares subject to this option vested on August 31, 2016, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer. Read SEC document |
| May 28, 2019 Filed May 30, 2019 20:56 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 18,000 | $50.00 | $900,000.00 |
DisclosureSEC source: 0001562180-19-003180 · primarydocument.xml · nonDerivative · entry 2 Simpson Curran · CIK 0001346164 · SVP, Product Development & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,500 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| May 28, 2019 Filed May 30, 2019 20:56 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 18,000 | $22.00 | $396,000.00 |
DisclosureSEC source: 0001562180-19-003180 · primarydocument.xml · nonDerivative · entry 1 Simpson Curran · CIK 0001346164 · SVP, Product Development & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 22:35 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,300 | $0.00 Strike: $35.80 | $0.00 |
DisclosureSEC source: 0001562180-19-001472 · primarydocument.xml · derivative · entry 3 Simpson Curran · CIK 0001346164 · SVP, Product Development & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,250 Underlying: Common Stock · 5,300 shares Expires 2028-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 55,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 3, 2019, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 22:35 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 5,300 | $54.05 | $286,465.00 |
DisclosureSEC source: 0001562180-19-001472 · primarydocument.xml · nonDerivative · entry 2 Simpson Curran · CIK 0001346164 · SVP, Product Development & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,500 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 22:35 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 5,300 | $35.80 | $189,740.00 |
DisclosureSEC source: 0001562180-19-001472 · primarydocument.xml · nonDerivative · entry 1 Simpson Curran · CIK 0001346164 · SVP, Product Development & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| February 05, 2019 Filed Feb 7, 2019 21:18 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Option (Right to Buy) · Derivative | 625 | $0.00 Strike: $13.09 | $0.00 |
DisclosureSEC source: 0001562180-19-000815 · primarydocument.xml · derivative · entry 9 Simpson Curran · CIK 0001346164 · SVP, Product Development & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,708 Underlying: Common Stock · 625 shares Expires 2026-01-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F6 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 10,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 28, 2017, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer. Read SEC document |
| February 05, 2019 Filed Feb 7, 2019 21:18 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,875 | $0.00 Strike: $19.50 | $0.00 |
DisclosureSEC source: 0001562180-19-000815 · primarydocument.xml · derivative · entry 8 Simpson Curran · CIK 0001346164 · SVP, Product Development & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 1,875 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F5 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 30,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 4, 2018, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer. Read SEC document |
| February 05, 2019 Filed Feb 7, 2019 21:18 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Option (Right to Buy) · Derivative | 32,882 | $0.00 Strike: $22.00 | $0.00 |
DisclosureSEC source: 0001562180-19-000815 · primarydocument.xml · derivative · entry 7 Simpson Curran · CIK 0001346164 · SVP, Product Development & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,219 Underlying: Common Stock · 32,882 shares Expires 2025-08-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 230,500 shares, became exercisable as follows: 25% of the shares subject to this option vested on August 31, 2016, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer. Read SEC document |
| February 05, 2019 Filed Feb 7, 2019 21:18 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,450 | $0.00 Strike: $35.80 | $0.00 |
DisclosureSEC source: 0001562180-19-000815 · primarydocument.xml · derivative · entry 6 Simpson Curran · CIK 0001346164 · SVP, Product Development & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,550 Underlying: Common Stock · 8,450 shares Expires 2028-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 55,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 3, 2019, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer. Read SEC document |
| February 05, 2019 Filed Feb 7, 2019 21:18 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 43,832 | $50.08 | $2,195,106.56 |
DisclosureSEC source: 0001562180-19-000815 · primarydocument.xml · nonDerivative · entry 5 Simpson Curran · CIK 0001346164 · SVP, Product Development & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,500 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $50.00 to $50.49. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 05, 2019 Filed Feb 7, 2019 21:18 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 625 | $13.09 | $8,181.25 |
DisclosureSEC source: 0001562180-19-000815 · primarydocument.xml · nonDerivative · entry 4 Simpson Curran · CIK 0001346164 · SVP, Product Development & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,332 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| February 05, 2019 Filed Feb 7, 2019 21:18 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 1,875 | $19.50 | $36,562.50 |
DisclosureSEC source: 0001562180-19-000815 · primarydocument.xml · nonDerivative · entry 3 Simpson Curran · CIK 0001346164 · SVP, Product Development & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,707 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| February 05, 2019 Filed Feb 7, 2019 21:18 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 32,882 | $22.00 | $723,404.00 |
DisclosureSEC source: 0001562180-19-000815 · primarydocument.xml · nonDerivative · entry 2 Simpson Curran · CIK 0001346164 · SVP, Product Development & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,832 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| February 05, 2019 Filed Feb 7, 2019 21:18 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 8,450 | $35.80 | $302,510.00 |
DisclosureSEC source: 0001562180-19-000815 · primarydocument.xml · nonDerivative · entry 1 Simpson Curran · CIK 0001346164 · SVP, Product Development & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,950 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 03, 2019 Filed Jan 7, 2019 21:25 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Option (Right to Buy) · Derivative | 46,000 | $0.00 Strike: $40.82 | $0.00 |
DisclosureSEC source: 0001562180-19-000221 · primarydocument.xml · derivative · entry 1 Simpson Curran · CIK 0001346164 · SVP, Product Development & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,000 Underlying: Common Stock · 46,000 shares Expires 2029-01-03 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 3, 2020 while the optionee provides continuous service to the Issuer. Read SEC document |
| November 16, 2018 Filed Nov 20, 2018 21:19 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Option (Right to Buy) · Derivative | 32,882 | $0.00 Strike: $22.00 | $0.00 |
DisclosureSEC source: 0001562180-18-004631 · primarydocument.xml · derivative · entry 6 Simpson Curran · CIK 0001346164 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,101 Underlying: Common Stock · 32,882 shares Expires 2025-08-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F6 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 230,500 shares, became exercisable as follows: 25% of the shares subject to this option vested on August 31, 2016, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer. Read SEC document |
| November 16, 2018 Filed Nov 20, 2018 21:19 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 15,494 | $64.71 | $1,002,616.74 |
DisclosureSEC source: 0001562180-18-004631 · primarydocument.xml · nonDerivative · entry 5 Simpson Curran · CIK 0001346164 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,500 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $64.30 to $65.16. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 16, 2018 Filed Nov 20, 2018 21:19 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 6,505 | $63.64 | $413,978.20 |
DisclosureSEC source: 0001562180-18-004631 · primarydocument.xml · nonDerivative · entry 4 Simpson Curran · CIK 0001346164 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,994 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $63.27 to $64.255. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 16, 2018 Filed Nov 20, 2018 21:19 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 6,883 | $62.79 | $432,183.57 |
DisclosureSEC source: 0001562180-18-004631 · primarydocument.xml · nonDerivative · entry 3 Simpson Curran · CIK 0001346164 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,499 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $62.25 to $63.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 16, 2018 Filed Nov 20, 2018 21:19 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 4,000 | $61.91 | $247,640.00 |
DisclosureSEC source: 0001562180-18-004631 · primarydocument.xml · nonDerivative · entry 2 Simpson Curran · CIK 0001346164 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,382 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $61.21 to $62.18. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 16, 2018 Filed Nov 20, 2018 21:19 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 32,882 | $22.00 | $723,404.00 |
DisclosureSEC source: 0001562180-18-004631 · primarydocument.xml · nonDerivative · entry 1 Simpson Curran · CIK 0001346164 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,382 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| October 16, 2018 Filed Oct 18, 2018 20:24 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,667 | $0.00 Strike: $13.09 | $0.00 |
DisclosureSEC source: 0001562180-18-004249 · primarydocument.xml · derivative · entry 9 Simpson Curran · CIK 0001346164 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,333 Underlying: Common Stock · 2,667 shares Expires 2026-01-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 10,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 28, 2017, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer. Read SEC document |
| October 16, 2018 Filed Oct 18, 2018 20:24 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,125 | $0.00 Strike: $19.50 | $0.00 |
DisclosureSEC source: 0001562180-18-004249 · primarydocument.xml · derivative · entry 8 Simpson Curran · CIK 0001346164 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,875 Underlying: Common Stock · 13,125 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 30,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 4, 2018, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer. Read SEC document |
| October 16, 2018 Filed Oct 18, 2018 20:24 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Option (Right to Buy) · Derivative | 46,517 | $0.00 Strike: $22.00 | $0.00 |
DisclosureSEC source: 0001562180-18-004249 · primarydocument.xml · derivative · entry 7 Simpson Curran · CIK 0001346164 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,983 Underlying: Common Stock · 46,517 shares Expires 2025-08-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 230,500 shares, became exercisable as follows: 25% of the shares subject to this option vested on August 31, 2016, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer. Read SEC document |
| October 16, 2018 Filed Oct 18, 2018 20:24 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 2,667 | $60.85 | $162,286.95 |
DisclosureSEC source: 0001562180-18-004249 · primarydocument.xml · nonDerivative · entry 6 Simpson Curran · CIK 0001346164 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,500 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| October 16, 2018 Filed Oct 18, 2018 20:24 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 2,667 | $13.09 | $34,911.03 |
DisclosureSEC source: 0001562180-18-004249 · primarydocument.xml · nonDerivative · entry 5 Simpson Curran · CIK 0001346164 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,167 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| October 16, 2018 Filed Oct 18, 2018 20:24 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 13,125 | $60.85 | $798,656.25 |
DisclosureSEC source: 0001562180-18-004249 · primarydocument.xml · nonDerivative · entry 4 Simpson Curran · CIK 0001346164 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,500 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| October 16, 2018 Filed Oct 18, 2018 20:24 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 13,125 | $19.50 | $255,937.50 |
DisclosureSEC source: 0001562180-18-004249 · primarydocument.xml · nonDerivative · entry 3 Simpson Curran · CIK 0001346164 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| October 16, 2018 Filed Oct 18, 2018 20:24 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 46,517 | $60.85 | $2,830,559.45 |
DisclosureSEC source: 0001562180-18-004249 · primarydocument.xml · nonDerivative · entry 2 Simpson Curran · CIK 0001346164 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,500 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.